Michael Frenneaux

Chief Scientific Officer

Professor Michael Frenneaux has more than 30 years of experience in clinical cardiology and research from the UK, New Zealand and Australia.
Prof. Frenneuax joined Imbria in July 2020 as Chief Scientific Officer. In addition, he has since May 2018 been the Chief of Scientific, Academic and Faculty Affairs, Academic Health System at Hamad Corporation with responsibility for the National Academic Health system as well as clinical research funding, governance, and training at Hamad Medical Corporation (Qatar’s national health system for secondary and tertiary care). He is Honorary Professor of Medicine at University of Aberdeen, Visiting Professor of Medicine at Imperial College, London, Adjunct Professor at the College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London. Prof. Frenneuax is also a Fellow of the Academy of Medical Sciences and has been a research panel member for the Medical Research Council, British Heart Foundation and Academy of Medical Sciences. He has held Programme Grants from the Medical Research Council and from the British Heart Foundation.

From 2015 Prof. Frenneuax was the Dean of Norwich Medical School at University of East Anglia. In 2009, he was appointed to the Regius Chair of Medicine in Aberdeen in 2009 (this is the oldest Chair of Medicine in the English-speaking world, established in 1497, and is appointed by the Queen) and prior to this was the British Heart Foundation (BHF) Sir Thomas Lewis Chair of Cardiology in Cardiff and BHF Chair of Cardiology in Birmingham.

Prof. Frenneaux’s research and clinical interest is centered around heart failure and heart muscle disease. His research is bed-to-bench and back to bedside. He is an integrated physiologist with wide interests, including the inorganic nitrate/nitrite axis, cardiac energetic impairment and metabolic therapies, vascular physiology as well as inter-ventricular and ventriculo-vascular coupling.